Wegovy review: is it worth it?
Wegovy (semaglutide 2.4mg) is an FDA-approved once-weekly injection for adults with obesity or overweight with comorbidities.
Status update: No formal taper required, but expect appetite return within 2-3 weeks and weight regain of ~2/3 of lost weight over 12 months without continued therapy{cite:1}. Pair discontinuation with behavioral support to preserve gains.
On this page
Strong, well-studied weight loss with real trade-offs
Strong, well-studied weight loss with real trade-offs
Wegovy is among the most effective FDA-approved weight-management medications, with average weight loss near 15% of body weight in pivotal trials and a documented 20% reduction in heart attack, stroke, and cardiovascular death in adults who have established cardiovascular disease and are overweight or obese (but do not have diabetes). It is not a quick fix: it requires weekly injections (or a newer daily pill), causes gastrointestinal side effects in most users, and works only as long as you keep taking it. For the right candidate willing to commit, the evidence base is strong, but the decision should be made with a prescriber.
- May be covered by insurance
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
- Personal or family history of medullary thyroid carcinoma (MTC). In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures; human relevance is not determined. Patients should be counseled to report symptoms of thyroid tumors (e.g., a neck mass, dysphagia, dyspnea, persistent hoarseness).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Wegovy is absolutely contraindicated in patients with MEN 2 because of the associated risk of medullary thyroid carcinoma.
- Prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with semaglutide.
- Pregnancy (per FDA label, when used for weight management): Weight loss offers no benefit during pregnancy and may cause fetal harm; animal data show embryofetal mortality, structural abnormalities, and growth alterations. Wegovy should be discontinued when pregnancy is recognized, and stopped at least 2 months before a planned pregnancy because of the drug's long half-life (washout). This is a labeled Use-in-Specific-Populations warning rather than a Section 4 absolute contraindication.
- Among the most effective FDA-approved weight-loss medications, with about 15% average body-weight reduction in large randomized trials (STEP 1 and STEP 5)
- Documented cardiovascular benefit: a 20% reduction in heart attack, stroke, and cardiovascular death in adults with established heart disease who are overweight or obese (SELECT trial)
- Once-weekly injection, with a newer once-daily oral pill option approved in December 2025 for patients who prefer to avoid needles
- Weight loss is sustained over 2 years with continued use, and the drug also tends to improve blood pressure, blood sugar, and waist circumference
- Backed by an extensive, high-quality evidence base (the STEP and SELECT programs) and a clearly defined FDA-approved label and safety profile
- Frequent gastrointestinal side effects (nausea, diarrhea, vomiting, constipation), especially during dose increases
- Weight is commonly regained after stopping; a STEP 1 extension found people regained about two-thirds of their lost weight within roughly a year, making it effectively a long-term commitment
- Ongoing cost and inconsistent coverage: about $349 per month cash for standard doses in 2026 (list price near $1,350), and many insurers, including most government plans, do not cover it for weight loss
- Carries a boxed warning for thyroid C-cell tumors and is contraindicated for people with a personal or family history of medullary thyroid cancer or MEN 2
- Requires gradual dose titration over about 4 months and ongoing medical supervision; it is not a fast or one-time solution
In-depth review
What is Wegovy and what is it FDA-approved for?
Wegovy is the brand name for semaglutide dosed at 2.4 mg once weekly, made by Novo Nordisk. It is the same molecule as Ozempic (the type 2 diabetes brand) and Rybelsus (the oral diabetes pill), but Wegovy is the version specifically approved and titrated for weight management at a higher target dose.
The FDA first approved Wegovy in June 2021 as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol (FDA). In late 2022 it was expanded to adolescents aged 12 and older with obesity (FDA).
In March 2024 the FDA approved a major new indication: reducing the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, and non-fatal stroke — in adults with established cardiovascular disease and either obesity or overweight (FDA). This made Wegovy the first weight-management medication shown to deliver a cardiovascular benefit, a distinction that matters because it reframes the drug as more than cosmetic.
Two things it is *not*: Wegovy is not approved purely for type 2 diabetes glucose control (that is Ozempic's lane), and it is not approved for people who simply want to lose a few pounds without meeting the BMI thresholds.
How does Wegovy work?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone your gut naturally releases after eating; it signals the pancreas to release insulin, suppresses the counter-hormone glucagon, and acts on the brain's appetite centers. Semaglutide mimics this hormone but is engineered to resist rapid breakdown, giving it a half-life of about a week — which is why it is dosed only once every seven days (NIH).
The weight-loss effect comes mainly from the brain, not the pancreas. Semaglutide acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger and increase satiety, so people feel full sooner and stay full longer. It also slows gastric emptying, meaning food leaves the stomach more slowly. The net result is a meaningful, mostly involuntary reduction in calorie intake. This mechanism also explains the most common side effects — nausea, fullness, and constipation are downstream of slowed digestion and suppressed appetite.
How well does Wegovy actually work?
This is where the evidence is genuinely strong. In the pivotal STEP 1 trial (1,961 adults with overweight/obesity but without diabetes), participants on semaglutide 2.4 mg plus lifestyle support lost an estimated mean of 14.9% of body weight at 68 weeks, versus 2.4% on placebo (NEJM 2021; PMID 33567185). About 86% reached at least 5% weight loss, and roughly one-third lost 20% or more — results that approach what some bariatric procedures achieve.
For an average 230-pound (104 kg) adult, 15% translates to about 34 pounds. Real-world results are typically somewhat lower than trial averages, partly because clinical-trial participants receive structured lifestyle counseling and partly because some people stop early due to side effects, cost, or supply.
The cardiovascular data give the drug a second, independent reason to take it. In the SELECT trial — 17,604 adults with established cardiovascular disease and overweight/obesity but no diabetes — semaglutide reduced the risk of major adverse cardiovascular events by 20% versus placebo over an average of about three years (NEJM 2023; PMID 37952131). Importantly, this benefit appeared early and was only partly explained by weight loss, suggesting direct cardiovascular and anti-inflammatory effects.
The catch: it only works while you take it
Obesity behaves like a chronic disease, and the trials show the effect is maintenance-dependent. In the STEP 4 withdrawal trial, people who switched to placebo after reaching the full dose regained weight (a 6.9% increase over the following 48 weeks), while those who continued semaglutide lost an additional ~7.9% (JAMA 2021; PMID 33755728). A one-year follow-up of STEP 1 found participants regained roughly two-thirds of their lost weight after stopping (Diabetes Obes Metab 2022). Practically, Wegovy is not a short course — it is an ongoing treatment, and budgeting and expectations should reflect that.
How is Wegovy dosed and titrated?
Wegovy is a once-weekly subcutaneous injection (abdomen, thigh, or upper arm) given on the same day each week, with or without food. Dosing is deliberately slow to limit nausea — the standard escalation runs over roughly 16 weeks (FDA label):
- Weeks 1–4: 0.25 mg/week (a "starter" dose with no expected weight effect; it lets the gut adapt)
- Weeks 5–8: 0.5 mg/week
- Weeks 9–12: 1 mg/week
- Weeks 13–16: 1.7 mg/week
- Week 17 onward: 2.4 mg/week (the maintenance/target dose)
If a particular step causes intolerable side effects, the prescriber can pause escalation or hold at a lower dose before advancing. Skipping the titration to "get there faster" reliably backfires with severe GI symptoms. A higher 7.2 mg formulation has also become available for some patients seeking additional effect; this should only be used under clinician guidance.
What are the side effects, warnings, and contraindications?
Common side effects are predominantly gastrointestinal and usually peak during dose escalation, then ease: nausea, diarrhea, vomiting, constipation, abdominal pain, and fatigue. They affect a large share of users to some degree, and are the main reason people discontinue. Eating smaller, lower-fat meals and stopping when full helps.
Serious but less common risks noted on the FDA label include:
- Pancreatitis — stop the drug and seek care for severe, persistent abdominal pain.
- Gallbladder problems including gallstones, partly linked to rapid weight loss.
- Acute kidney injury, usually from dehydration driven by vomiting/diarrhea.
- Diabetic retinopathy complications in people with type 2 diabetes.
- Hypoglycemia when combined with insulin or sulfonylureas.
- Gastroparesis / severe delayed stomach emptying — relevant for anyone undergoing anesthesia, since retained stomach contents raise aspiration risk; tell your surgical team you take a GLP-1.
Boxed warning and contraindications: Wegovy carries an FDA boxed warning for thyroid C-cell tumors, based on rodent studies showing medullary thyroid carcinoma (the human relevance is unconfirmed). It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in those with a known serious hypersensitivity to semaglutide (FDA).
Avoid in pregnancy. Semaglutide should be stopped at least two months before a planned pregnancy because of its long half-life and animal data suggesting fetal harm (FDA).
Interactions are mostly mechanical rather than chemical: delayed gastric emptying can alter the absorption of oral medications, and insulin/sulfonylurea doses often need lowering to prevent hypoglycemia.
Who is Wegovy best for — and who should skip it?
A strong fit if you: meet the BMI criteria (≥30, or ≥27 with a weight-related condition); have struggled with sustained weight loss through diet and exercise alone; have established cardiovascular disease (where the SELECT benefit applies); and are prepared to treat obesity as a long-term, ongoing condition rather than a quick fix.
Reconsider or avoid if you: have a personal or family history of MTC or MEN 2; have had pancreatitis; are pregnant, breastfeeding, or planning pregnancy soon; have severe gastroparesis or a history of significant GI disease; or cannot realistically sustain the cost long-term, since stopping tends to reverse the gains. People seeking modest cosmetic weight loss without meeting clinical criteria are not appropriate candidates, and the drug should always be paired with nutrition and activity changes — the trials all included lifestyle support.
What does Wegovy cost and how do you access it?
Wegovy's list price is about $1,349 per month, but very few people pay that. With commercial insurance coverage, eligible patients may pay far less through Novo Nordisk savings programs. The bigger story for the uninsured or unreimbursed is the manufacturer's cash-pay option through NovoCare Pharmacy: as of late 2025 Novo Nordisk lowered the standard self-pay price to about $349/month for the maintenance strengths (down from $499), with a reduced introductory price for the first one to two months of the lower starter doses and a slightly higher self-pay price for the new 7.2 mg strength. Always confirm current pricing directly with NovoCare or your pharmacy, as these programs change frequently.
The two practical hurdles are coverage and supply. Many commercial plans require prior authorization or exclude obesity drugs entirely; Medicare historically did not cover medications used purely for weight loss, though the cardiovascular indication has opened some coverage pathways for patients with qualifying heart disease. After years of intermittent shortages, supply has largely stabilized.
A word of caution on compounded semaglutide: telehealth platforms still advertise compounded versions at roughly $99–$269/month, though the gap versus brand self-pay has narrowed now that NovoCare's cash price has dropped. More importantly, compounded products are not FDA-approved, are not the identical Novo Nordisk product, and now that semaglutide is off the FDA shortage list (since early 2025), large-scale compounding is far more restricted and generally limited to documented clinical need. Quality, dosing accuracy, and the actual active ingredient (some have used semaglutide salts of uncertain equivalence) vary. Treat cheap compounded GLP-1s with real skepticism.
How does Wegovy compare to the alternatives?
Wegovy vs. Zepbound (tirzepatide): This is the central comparison in 2026, and the head-to-head data favor Zepbound for raw weight loss. In SURMOUNT-5, the first direct trial, tirzepatide produced a mean 20.2% weight loss versus 13.7% for semaglutide at 72 weeks (NEJM 2025; PMID 40353578). Zepbound is a dual GIP/GLP-1 agonist, which appears to drive the larger effect, and it also had fewer GI-related discontinuations in that trial. Wegovy's counterweight is its proven cardiovascular outcomes data (SELECT), which Zepbound does not yet match for that specific indication. If maximum weight loss is the goal, the evidence leans Zepbound; if you have established heart disease, Wegovy has the clearer outcomes case.
Wegovy vs. Saxenda (liraglutide): Older daily GLP-1. In the STEP 8 head-to-head, semaglutide produced 15.8% weight loss versus 6.4% for liraglutide at 68 weeks (JAMA 2022; PMID 35017634) — Wegovy is clearly more effective and requires only weekly rather than daily injections.
Wegovy vs. Ozempic: Same molecule, different approved use and max dose. Ozempic is approved for diabetes and tops out at 2 mg; Wegovy is titrated to 2.4 mg for weight management. Using Ozempic "off-label" for weight loss is common but means no obesity-specific approval and inconsistent coverage.
Wegovy vs. the oral pill: An oral version of Wegovy (semaglutide 25 mg, once daily) was FDA-approved for chronic weight management — the first oral GLP-1 cleared for weight loss — based on the OASIS program, which showed roughly 16.6% mean weight loss at 64 weeks with full adherence. The pill offers needle-free convenience, though its average effect in trials was somewhat below the ~15-17% seen with the injection and it must be taken daily on an empty stomach with strict timing rules. For maximum weight loss the injectable formulation still has the deeper outcomes record (including the SELECT cardiovascular data), but the oral option is now a legitimate alternative for people who prefer to avoid injections.
The bottom line
Wegovy is one of the most effective non-surgical obesity treatments ever brought to market, with about 15% average weight loss in trials, a genuine and independently valuable cardiovascular benefit for people with heart disease, and a strong, transparent evidence base behind it. Its real limitations are honest ones: it is a chronic, indefinite therapy (weight returns when you stop), it commonly causes GI side effects during titration, it carries specific contraindications, and cost plus coverage remain the biggest practical barriers for most people. If you meet the clinical criteria and can sustain it, Wegovy is a well-supported choice — though anyone prioritizing the greatest possible weight loss should weigh the head-to-head data favoring tirzepatide (Zepbound), and everyone should treat it as one part of a long-term, medically supervised plan rather than a standalone solution. Decisions about starting, switching, or stopping should be made with a licensed clinician who knows your full history.
*This article is for educational purposes and is not medical advice. HealthVetted is independent, accepts no payment for placement, and sells none of the products it reviews.*
How it works
Wegovy's active ingredient, semaglutide, mimics a natural gut hormone called GLP-1 (glucagon-like peptide-1). By activating GLP-1 receptors in the brain's appetite centers, it reduces hunger, increases feelings of fullness, and slows how quickly the stomach empties. The result is that most people naturally eat less and feel satisfied on smaller portions. It also improves how the body handles blood sugar. Because it does not "burn fat" directly, it works largely by lowering calorie intake, which is why diet and physical activity remain part of treatment.
Active ingredient: Semaglutide
Effectiveness
In the pivotal STEP 1 trial (NEJM, 2021; 1,961 adults with overweight or obesity but without diabetes), weekly semaglutide 2.4 mg produced an average weight loss of about 14.9% of body weight at 68 weeks versus roughly 2.4% with placebo, and about 86% of treated participants lost at least 5% of their body weight. The 2-year STEP 5 trial (Nature Medicine, 2022) showed sustained results with continued use: about 15.2% mean weight loss versus 2.6% with placebo at 104 weeks. In the large SELECT cardiovascular outcomes trial (NEJM, 2023; 17,604 adults with established cardiovascular disease, overweight or obese, without diabetes), semaglutide reduced major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) by 20% versus placebo (hazard ratio 0.80). The newer oral Wegovy 25 mg pill produced about 16.6% mean weight loss among participants who adhered to treatment in the OASIS 4 trial. Individual results vary.
What to expect over time
A realistic timeline of what Wegovy users typically experience. Individual results vary; this is educational, not medical advice.
- Weeks 1-4 (starting dose 0.25 mg)
You begin at 0.25 mg injected once weekly - a deliberately low "starter" dose meant to let your body adjust, not to drive weight loss. Mild GI side effects (nausea, fullness, constipation) are most common in this window; many people also notice early appetite changes or quieter "food noise." Significant scale movement is not expected yet.
- Weeks 5-16 (titration: 0.5 to 1.7 mg)
The dose steps up roughly every 4 weeks (0.5, then 1.0, then 1.7 mg) so your body acclimates gradually. Nausea or queasiness often flares briefly after each increase and usually eases within days to a couple of weeks. Measurable weight loss typically begins in this phase, with appetite suppression becoming more noticeable as the dose rises.
- Month 5 onward (maintenance 2.4 mg)
Most reach the full 2.4 mg maintenance dose around week 16-20 (some stay at 1.7 mg if it works well and is tolerated). Weight loss tends to accelerate at the higher doses. Side effects generally settle as you stabilize, though individual tolerance varies.
- Around month 6
In the STEP 1 trial, many participants had lost roughly 10-15% of starting body weight by this point, though results vary widely - some lose more, some less, and a minority respond minimally. Loss is gradual and depends on adherence plus diet and activity.
- Months 12-18 (plateau)
Average total weight loss in STEP 1 was about 14.9% at 68 weeks (versus ~2.4% on placebo). Weight loss usually slows and plateaus somewhere in this period as your body reaches a new set point. This is expected, not a sign the medication has stopped working.
- Ongoing (long-term)
Wegovy is intended for long-term, chronic use under medical supervision; it manages weight rather than curing obesity. Studies show weight tends to be regained after stopping, so maintaining results generally means continuing treatment alongside lifestyle changes. Discuss duration, monitoring, and any persistent side effects with your prescriber.
Side effects
The most common side effects (each occurring in 5% or more of users in trials) are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, bloating, and indigestion, along with headache, fatigue, and dizziness. These are usually mild to moderate, tend to be worst when starting or increasing the dose, and often ease over a few weeks. Serious but less common risks include pancreatitis, gallbladder problems (including gallstones), acute kidney injury from dehydration caused by vomiting or diarrhea, low blood sugar (mainly in people also taking diabetes medications such as insulin or sulfonylureas), and worsening of diabetic eye disease. Wegovy carries a boxed warning for thyroid C-cell tumors based on rodent studies; whether this risk applies to humans is not known. Seek medical care promptly for severe, persistent abdominal pain (a possible sign of pancreatitis). This is not a complete list; review the full label and discuss risks with your prescriber.
- Nausea · common
- Diarrhea · common
- Constipation · common
- Pancreatitis · serious
- Gallbladder problems · uncommon
Safety: who should avoid it & interactions
- ✕Personal or family history of medullary thyroid carcinoma (MTC). In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures; human relevance is not determined. Patients should be counseled to report symptoms of thyroid tumors (e.g., a neck mass, dysphagia, dyspnea, persistent hoarseness).
- ✕Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Wegovy is absolutely contraindicated in patients with MEN 2 because of the associated risk of medullary thyroid carcinoma.
- ✕Prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with semaglutide.
- ✕Pregnancy (per FDA label, when used for weight management): Weight loss offers no benefit during pregnancy and may cause fetal harm; animal data show embryofetal mortality, structural abnormalities, and growth alterations. Wegovy should be discontinued when pregnancy is recognized, and stopped at least 2 months before a planned pregnancy because of the drug's long half-life (washout). This is a labeled Use-in-Specific-Populations warning rather than a Section 4 absolute contraindication.
- MajorInsulin and insulin secretagogues (e.g., sulfonylureas such as glipizide, glimepiride, glyburide): Concomitant use increases the risk of hypoglycemia, including severe hypoglycemia, in patients with type 2 diabetes. When initiating Wegovy, consider reducing the dose of the concomitantly administered insulin or insulin secretagogue, and counsel patients on the signs, symptoms, and management of hypoglycemia. (FDA Wegovy label (DailyMed), Drug Interactions 7.1 and Warnings & Precautions 5.4)
- ModerateOral medications generally (delayed gastric emptying): Wegovy delays gastric emptying and may affect the absorption of concomitantly administered oral drugs. Monitor the effects of oral medications taken with Wegovy. (FDA Wegovy label (DailyMed), Drug Interactions 7.2)
- ModerateNarrow therapeutic index oral drugs (e.g., warfarin, digoxin, phenytoin, lithium): Because Wegovy delays gastric emptying and may alter the rate/extent of oral drug absorption, consider increased clinical and/or laboratory monitoring for medications with a narrow therapeutic index (for example, INR monitoring with warfarin). (FDA Wegovy label (DailyMed), Drug Interactions 7.2)
- ModerateLevothyroxine: Total levothyroxine exposure (AUC) increased about 33% when co-administered with semaglutide, likely related to delayed gastric emptying. Monitor thyroid function (e.g., TSH) in patients treated with levothyroxine while on Wegovy. (FDA Wegovy label (DailyMed), Drug Interactions 7.2 / Clinical Pharmacology 12.3)
- MajorOther GLP-1 receptor agonists and other semaglutide-containing products (e.g., Ozempic, Rybelsus, Saxenda/liraglutide, dulaglutide, tirzepatide): Wegovy should not be co-administered with other semaglutide-containing products or other GLP-1 receptor agonists; doing so increases the risk of additive adverse effects (e.g., GI effects, hypoglycemia) without added benefit. Additionally, use caution in patients with a prior history of anaphylaxis or angioedema to another GLP-1 receptor agonist, as it is unknown whether they are predisposed to these reactions with Wegovy. (FDA Wegovy label (DailyMed); prescribing information / Warnings & Precautions)
Sourced from FDA labeling and clinical references; not exhaustive and not a substitute for your prescriber or pharmacist. Always disclose every medication and supplement you take.
Cost
Starts at $349/mo from Novo Nordisk.
As of September 2026, Wegovy's list price is $1,349.02 per package, but cash-paying patients rarely pay that: NovoCare's self-pay price is $349/month for the 0.25–2.4 mg pens and $399/month for Wegovy HD 7.2 mg, and new patients pay $199/month for their first two fills of 0.25 mg or 0.5 mg through December 31, 2026. The Wegovy pill has separate self-pay pricing starting at $149/month. With commercial insurance that covers Wegovy, the manufacturer savings card can lower the copay further for eligible patients, but many plans — and most Medicare and Medicaid plans — still exclude weight-loss drugs. Verify pricing for your dose with NovoCare before starting.
NovoCare self-pay (checked Sept 15, 2026): $349/month for Wegovy pen 0.25–2.4 mg; $399/month for Wegovy HD 7.2 mg. New patients pay $199/month for the first two fills of 0.25 mg or 0.5 mg (through Dec 31, 2026). List price: $1,349.02 per package.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
Is it worth it?
Wegovy delivers some of the strongest non-surgical weight-loss results available, backed by large randomized trials and a documented cardiovascular benefit in one high-risk population. The trade-offs are real: frequent GI side effects, ongoing cost if uninsured, and weight regain when you stop. For people with obesity, or overweight plus a weight-related condition, it is one of the most effective options available in 2026 if you can sustain it. This is a prescription medication; only a clinician can decide whether it is right for you.
Frequently asked questions
How much weight can you lose on Wegovy?
In the pivotal STEP 1 trial, adults with overweight or obesity but without diabetes lost an average of about 15% of their body weight over 68 weeks on weekly semaglutide 2.4 mg, compared with about 2% on placebo. About 86% of treated participants lost at least 5% of their weight. Individual results vary, and weight loss is greatest when the medication is combined with a reduced-calorie diet and increased activity.
What is the difference between Wegovy and Ozempic?
Both Wegovy and Ozempic contain the same active drug, semaglutide, but they are approved for different uses. Wegovy is FDA-approved for chronic weight management at a higher maximum dose (2.4 mg), while Ozempic is approved for type 2 diabetes (maximum 2 mg). They are not interchangeable and use different pens and dosing schedules. Your prescriber decides which, if either, is appropriate.
How much does Wegovy cost without insurance in 2026?
Wegovy's list price is roughly $1,350 per month. As of 2026, Novo Nordisk's NovoCare self-pay program offers the injection to eligible cash-paying patients for about $349 per month for standard doses, with a limited-time promotional price near $199 per month for the lowest starter doses through mid-2026. With commercial insurance that covers Wegovy, the manufacturer savings card can lower copays for eligible patients, but many plans do not cover it for weight loss. Prices change often, so confirm current pricing with NovoCare and your pharmacy.
What happens when you stop taking Wegovy?
Most people regain a significant portion of their lost weight after stopping, because appetite and hunger signals return toward baseline. In the STEP 1 trial extension, participants regained about two-thirds of their lost weight within roughly a year of stopping. For this reason, Wegovy is generally considered a long-term treatment rather than a short course. Talk to your prescriber before changing or stopping the medication.
What are the most common side effects of Wegovy?
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain. They are usually mild to moderate, tend to be worst when the dose is being increased, and often improve within a few weeks. Less common but serious risks include pancreatitis and gallbladder problems. Seek medical care for severe, persistent abdominal pain, and review the full label with your prescriber.
Who should not take Wegovy?
Wegovy should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or by those with a known serious allergy to semaglutide. It should not be used during pregnancy and, because of the drug's long half-life, the label advises stopping at least 2 months before a planned pregnancy. People with a history of pancreatitis, gallbladder disease, or kidney problems should use it cautiously and only under medical supervision.
Is there a Wegovy pill, and how does it compare to the injection?
Yes. The FDA approved an oral Wegovy 25 mg tablet on December 22, 2025, with a US launch in early 2026. In the OASIS 4 trial it produced about 16.6% mean weight loss among participants who adhered to treatment, broadly comparable to the injection, but it must be taken daily on an empty stomach with strict timing rules (no other food, drink, or medication for 30 minutes after). Your prescriber can advise which form suits you.
How long does it take for Wegovy to start working?
Many people notice reduced appetite within the first few weeks, but the dose is increased gradually over about 16 weeks, and meaningful weight loss typically builds over several months. In the pivotal trials, the largest results were measured at 68 weeks and beyond, so it is best viewed as a long-term treatment.
Does Wegovy reduce heart attack and stroke risk?
Yes, in a specific group. The SELECT trial of 17,604 adults who had established cardiovascular disease and were overweight or obese (without diabetes) found that Wegovy reduced major cardiovascular events (cardiovascular death, non-fatal heart attack, and non-fatal stroke) by 20% versus placebo. This led to an FDA-approved cardiovascular indication for adults with established heart disease who are overweight or obese. The benefit has not been demonstrated in lower-risk groups.
Sources
- WEGOVY (semaglutide) injection/tablet — Full Prescribing Information (Label) — DailyMed, U.S. National Library of Medicine (Novo Nordisk) (2026)
- WEGOVY (semaglutide) injection 2.4 mg — Highlights of Prescribing Information (FDA-approved label) — U.S. Food and Drug Administration (Drugs@FDA) (2023)
- FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight — U.S. Food and Drug Administration (Press Announcement) (2024)
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine (2021)
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial — The Lancet (2021)
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial — JAMA (2021)
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial (PubMed record) — JAMA (PubMed, PMID 33755728) (2021)
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — New England Journal of Medicine (2023)
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial — Nature Medicine (PMC) (2022)
- Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS) — New England Journal of Medicine (2022)
- Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review — Diabetes, Metabolic Syndrome and Obesity (PMC) (2022)
- Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation — The American Journal of Medicine (2025)
- Evaluating the safety profile of semaglutide: an updated meta-analysis — PubMed (PMID 39046272) (2024)
- Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis — Medicine (Baltimore) (PMC) (2024)
- Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on the FDA Adverse Event Reporting System — Frontiers in Public Health (2022)
- Prescription Medications to Treat Overweight & Obesity — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH (2025)
- Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial — The Lancet Diabetes & Endocrinology (2024)
- Novo Nordisk receives FDA approval for Wegovy to treat adults with obesity (company news release) — Novo Nordisk (PR Newswire) (2021)
Ready to try Wegovy?
Check eligibility & price — from $349/mo- May be covered by insurance
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Related guides
Ways to save on Wegovy
Legitimate ways to lower your cost. We don’t sell Wegovy — this is independent guidance, not medical or financial advice. Confirm current terms with the program and your clinician.
- Manufacturer savings program
The maker of Wegovy runs a commercial-insurance savings program that can lower your copay. See the official Wegovy savings page → Eligibility rules apply and these programs typically exclude government insurance (Medicare/Medicaid).
- Patient assistance programs (PAPs)
If you’re uninsured or low-income, free or reduced-cost medication may be available through patient assistance programs. Search MedicineAssistanceTool (PhRMA) and NeedyMeds.
- Ask about a 90-day supply
Filling a 90-day supply instead of monthly often lowers the per-month cost and cuts pharmacy trips. Ask your prescriber and pharmacy whether it’s an option for you.
- Compare lower-cost alternatives
A different formulation or product may cost less for a similar result. Compounded GLP-1 · Supplements vs GLP-1.
How Wegovy compares
Same-category options, scored on the same six-axis rubric. Higher is better.